Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.42 |
| ▸ | ITGAV | P06756 | 4/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7262653 | 0.89 | ITGB3 (0.52) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7262649 | 0.89 | ITGB3 (0.52) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL8080233 | 0.86 | ITGB3 (0.36) | ITGB3ITGA2BCA2TGFBR1 | |
| SCHEMBL7406599 | 0.82 | ITGB3 (0.41) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL7656989 | 0.81 | ITGB3 (0.49) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL7066123 | 0.80 | ALDH1A1 (0.47) | CA2 | |
| SCHEMBL2971515 | 0.77 | ITGB3 (0.36) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL20335141 | 0.76 | LMNA (0.50) | CA2 | |
| SCHEMBL20335140 | 0.76 | LMNA (0.50) | CA2 | |
| SCHEMBL7144029 | 0.76 | ITGB3 (0.53) | ITGB3ITGA2BITGAVCHRM2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1051625-A1 | ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES | Du Pont Pharmaceuticals Company (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999038014-A1 | ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |